The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001031358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
2/04/2026
Date registered
Help: Date registered
21/08/2026
Date last updated
Help: Date last updated
21/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
21/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A First-in-human Phase-1 PET Imaging Study of [64Cu]IS1051 in Participants with Suspected Infection
Scientific title
A First-in-Human Phase 1 Study of [64Cu]IS1051 PET Imaging to Evaluate Safety, Biodistribution, and Detection of Bacterial Infection in Adults
Additional trial identifiers [1] 316924 0
Nil
Universal Trial Number (UTN)
Trial acronym
PUREVIEW
Related trial records

Health condition
Health condition(s) studied:
Infection 341347 0
Condition category
Condition code
Infection 337417 337417 0 0
Studies of infection and infectious agents
Infection 337418 337418 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
[64Cu]IS1051is a novel, radioactive small-molecule ligand that binds specifically to LFA-1, a leukocyte surface integrin involved in immune-cell adhesion and migration. Radiolabelling with copper-64 (64Cu; half-life 12.7 h) results in the final injectable PET radiopharmaceutical investigational medical product (IMP) [64Cu]IS1051, to enable PET imaging over extended time windows.

This first-in-human (FIH) study will enrol adult participants who have undergone standard of care (SoC) diagnostic imaging (e.g., radiolabelled autologous White blood cell (WBC) imaging, or 67Ga-scintigraphy) with findings consistent with a suspected bacterial origin. This population represents patients with a high likelihood of bacterial infection, in whom improved diagnostic accuracy may directly impact clinical management and outcomes.

Administration of [64Cu]IS1051: This study will involve a single administration of [64Cu]IS1051 within a defined diagnostic activity range.

There is no randomization, blinding, or placebo control in this study.

Details of the intervention are as follows:
Procedures and/or processes used - Imaging
Unit Dose Strength(s) - 150–300 MBq (4–8 mCi), <40 µg in <10 mL
Duration of the intervention - 7 days
Who will administer [64Cu]IS1051 - Principal Investigator
Any strategies used to assess or monitor adherence to the intervention - Patient medical records, inpatient visit/monitoring

Imaging Procedures: PET/CT imaging will be conducted at predefined timepoints following administration of [64Cu]IS1051 to assess biodistribution, dosimetry, and tracer kinetics (e.g., dynamic 0–30 minutes, static ~1 h, 3 h, 6 h, and 24 h post-injection).

As this is a tracer-level radiopharmaceutical without pharmacologic activity, dose adjustment will be based on participant characteristics (e.g., age, sex, body weight) is not required according to protocol,





Intervention code [1] 333639 0
Treatment: Drugs
Intervention code [2] 333640 0
Diagnosis / Prognosis
Intervention code [3] 333641 0
Early detection / Screening
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344941 0
To evaluate the safety and tolerability of a single intravenous administration of IS-1051 in adult participants with suspected bacterial infection safety and tolerability will be assessed as a composite primary outcome.
Timepoint [1] 344941 0
Safety laboratory assessment (hematology, coagulation, biochemistry, urinalysis) parameters will be summarized at baseline and Day 7 (± 2 days) visits Specification of timepoints: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) from baseline through Day 7 ± 2 days, graded by CTCAE v6.0 Vital signs to be taken at screening, Predose/baseline, post dose +/- 15 minutes and only if clinically indicated at 2hrs,4 hrs,6 hrs,8 hrs. 12 lead ECG: at Screening, Predose/baseline assessment, post injection (0-8h) Physical examination: Screening, Predose/baseline assessment, post injection if indicated (0-8h), Day 7 follow up if indicated.
Primary outcome [2] 344942 0
Clinically significant changes from baseline in vital signs, 12-lead ECG parameters, and laboratory assessments through Day 7 ± 2 days This will be assessed as a composite outcome. ECG parameters that are being assessed are PR, QRS, QT/QTc intervals, heart rate. Standard 12-lead ECGs will be performed at screening and after dosing. Study participants will only be registered if the ECG is normal, or any abnormalities that are noted are considered by the investigator to be not clinically relevant with the exception of QTc interval. Participants with a screening ECG demonstrating a QTc interval more than 450 ms (males) or more than 470 ms (females), will be excluded from study participation.
Timepoint [2] 344942 0
From baseline through Day 7 ± 2 days
Secondary outcome [1] 459877 0
To characterize the biodistribution and pharmacokinetics of [64Cu]IS1051 using PET/CT imaging. Biodistribution and pharmacokinetics will be assessed as a composite outcome
Timepoint [1] 459877 0
Imaging timepoints (1 h, 3 h, 6 h, 24 h post-injection)

Eligibility
Key inclusion criteria
1. Age more than or equal to 18 years.
2. Able to provide written informed consent and comply with all study procedures.
3. Fluent in English, or an interpreter is available to ensure adequate understanding of the consent process and study participation.
4. Willing and able to undergo PET/CT imaging as scheduled.
5. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and pre-dosing and agree to use an effective method for at least 6 months after the last dose. Men with partners of childbearing potential must agree not to father a child or donate sperm for at least 3 months after the last dose of the study medication.
6. Clinically stable and suitable for imaging procedures at the time of enrolment.
7. Adequate renal and hepatic function based on recent (local SoC or screening) laboratory values within acceptable limits for study participation:
estimated glomerular filtration rate (estimated glomerular filtration rate [eGFR] is more than or equal to 45 mL/min/1.73 m²; alanine aminotransferase/aspartate aminotransferase [ALT/AST] less than or equal to 3 × upper limit of normal [ULN]; total bilirubin less than or equal to 3 × ULN).
8. No contraindication to PET/CT scanning or intravenous injection (e.g. severe claustrophobia, inability to lie supine for approximately 60 minutes, or contrast allergy
9. Body weight less than or equal to 150 kg (to ensure scanner table and field-of-view compatibility).
10. Not participating in another investigational intervention study or research involving ionising radiation within 30 days prior to screening.
11. Clinically suspected infection associated with prosthetic material, implanted device, and/or bone, joint, or soft tissue involvement, supported by microbiological OR laboratory evidence (e.g. positive blood culture, elevated inflammatory markers, OR leukocytosis).
12. Positive imaging findings on ¹8F-FDG PET/CT, radiolabelled WBC scan, or 67Ga scintigraphy consistent with a bacterial infection

Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Known active malignancy
2. Severe cardiopulmonary disease (e.g., New York Heart Association [NYHA] class IV heart failure, GOLD stage IV COPD)
3. Hemodynamic instability or uncontrolled systemic illness
4. Neutropenia (absolute neutrophil count [ANC] 450 ms (males) or >470 ms (females)
8. Any medical, psychiatric, or cognitive condition that may interfere with study compliance or increase risk, per investigator judgment
9. Scheduled administration of a diagnostic radiopharmaceutical within 48 hours before or after 64Cu-IS1051 imaging, by which such extra nuclear study may interfere with the [64Cu]IS1051 imaging study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
• Demographics: age, sex, height, weight, body mass index (BMI).
• Clinical characteristics: vital signs, baseline laboratory parameters, ECG findings.
• Medical history: relevant comorbidities, history of infection or inflammation, and use of antibiotics or immunomodulatory therapies.
• Baseline disease characteristics: site and type of suspected infection, recent SoC imaging results (¹8F-FDG PET/CT, labelled WBC, 67Ga).
• Prior and concomitant medications: including antibiotic classes, corticosteroids
Summaries will be descriptive, using counts, percentages, means, standard deviations, medians, and ranges, as appropriate. No formal statistical comparisons are planned for baseline variables.

These data will be summarized for all enrolled participants (Safety Set and Imaging Set, as applicable) to provide context for interpretation of safety, dosimetry, and imaging outcomes.

The sample size selected in this study is not based on formal statistical hypothesis testing and therefore power calculations are not required. The number of participants is based on safety and feasibility and is similar to other dosimetry studies.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29357 0
St Vincent's Private Hospital - Fitzroy
Recruitment postcode(s) [1] 45676 0
3065 - Fitzroy

Funding & Sponsors
Funding source category [1] 321519 0
Commercial sector/Industry
Name [1] 321519 0
iSeek Biopharma AU Pty Ltd
Country [1] 321519 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
iSeek Biopharma AU Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324284 0
None
Name [1] 324284 0
Address [1] 324284 0
Country [1] 324284 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320053 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 320053 0
Ethics committee country [1] 320053 0
Australia
Date submitted for ethics approval [1] 320053 0
07/04/2026
Approval date [1] 320053 0
08/07/2026
Ethics approval number [1] 320053 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149278 0
A/Prof Kim Taubman
Address 149278 0
St Vincents Hospital Melbourne Level 3 Daly Wing, 35 Victoria Pde Fitzroy, VIC, 3065
Country 149278 0
Australia
Phone 149278 0
+61 3 9231 4310
Fax 149278 0
Email 149278 0
Contact person for public queries
Name 149279 0
Dr Sam Vohra
Address 149279 0
Avion Medical CRO 141 Camberwell Rd, Hawthorn VIC 3122
Country 149279 0
Australia
Phone 149279 0
+61 450 556 969
Fax 149279 0
Email 149279 0
Contact person for scientific queries
Name 149280 0
Boudewijn Krenning
Address 149280 0
iSeek Biopharma ISEEK BIOPHARMA AU PTY LTD, 29 Water St Suite 203 Newburyport MA 01950-2763
Country 149280 0
United States of America
Phone 149280 0
+31 619182626
Fax 149280 0
Email 149280 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.